Nurdan Gönül Baltacı

Nurdan Gönül Baltacı

Auto-generated profile, based on publicly available information

Nurdan Gönül Baltacı

Department of Molecular Biology and Genetics, Faculty of Science, Ataturk University, Erzurum, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Environmental Science and Pollution Research
Verified
Journal Article
Open access
PDF file
NBNurdan Gönül Baltacı
Nurdan Gönül Baltacı
MBMustafa Özkan Baltacı
Mustafa Özkan Baltacı
AGArzu Görmez
Arzu Görmez
SÖSerkan Örtücü
Serkan Örtücü
Polyhydroxyalkanoates have attracted great interest as a suitable alternative to petrochemical based plastics due to their outstanding properties such as biodegradability and biocompatibility. However, the biggest problem in the production of microbial polyhydroxyalkanoates is low cost-effectiveness. In this study, polyhydroxyalkanoate production was carried out using waste substrates with local isolates. Culture conditions were optimized to increase the polyhydroxyalkanoate production potential. The produced polyhydroxyalkanoate was characterized by FTIR analyses, and its metabolic pathway was determined by real-time PCR. According to the results, the best polyhydroxyalkanoate producer bacteria was characterized as Pseudomonas neustonica NGB15. The optimal culture conditions were detected as 30 g/L banana peel powder, 25 °C temperature, pH 8, and 4-day incubation time. Under the optimized conditions, 3.34 g/L PHA production was achieved. As a result of FTIR analyses, major peaks were obtained at 1723, 1277, 1261, 1097, 1054, and 993 cm−1. These peaks represent that the type of produced polyhydroxyalkanoate was poly-β-hydroxybutyrate. According to gene expression profile of NGB15, it was determined that Pseudomonas neustonica NGB15 produces PHA using the de novo fatty acid synthesis metabolic pathway. In conclusion, poly-β-hydroxybutyrate production by Pseudomonas neustonica NGB15 using a low-cost fermentation medium has been shown to be biotechnologically promising.

15 November 2022 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
EKEnver Fehim Koçpınar
Enver Fehim Koçpınar
NBNurdan Gonul Baltaci
Nurdan Gonul Baltaci
EAEbru Akkemik
Ebru Akkemik
HBHarun Budak
Harun Budak

7 September 2025 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
NBNurdan Gönül Baltacı
Nurdan Gönül Baltacı
KBKübra Nur Bayındırlı
Kübra Nur Bayındırlı
MBMUSTAFA OZKAN BALTACI
MUSTAFA OZKAN BALTACI

4 December 2025 in Waste and Biomass Valorization
Verified
Journal Article
Closed access
PDF file
NBNurdan Gönül Baltacı
Nurdan Gönül Baltacı

3 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NTNuman Taspinar
Numan Taspinar
AHAhmet Hacimuftuoglu
Ahmet Hacimuftuoglu
DBDamla Binnetoglu
Damla Binnetoglu
EKEnver Fehim Koçpınar
Enver Fehim Koçpınar
NBNurdan Gonul Baltaci
Nurdan Gonul Baltaci
A. M. Abd El-AtyA. M. Abd El-Aty
A. M. Abd El-Aty
Ceftriaxone has shown promise as a neuroprotective agent through its modulation of glutamate transporters, yet its precise role in chronic pain remains underexplored. This study aimed to investigate the central mechanisms underlying the transition to chronic pain, focusing on glutamatergic activity in the primary somatosensory cortex hind limb (S1HL) and posterior intralaminar thalamic nucleus (PIL) in a rat model. Female Wistar rats (n = 36) were randomly assigned to six groups. Neuropathic pain was induced using paclitaxel (2 mg/kg, administered intraperitoneally on days 0, 2, 4, and 6). Starting on day 27, animals received daily intraperitoneal treatment for 10 days with either ceftriaxone (200 mg/kg), penicillin (400,000 U/kg), clonidine (2.5 µg/kg), morphine (0.1 mg/kg), or saline (control). Ceftriaxone treatment significantly increased pain thresholds. Voltammetry analysis showed that glutamate reuptake time (T80) in the S1HL cortex, which was prolonged to approximately 8 s in the paclitaxel group, returned to near-normal values (3–3.5 s) with ceftriaxone. Gene expression analyses revealed that ceftriaxone upregulated all assessed glutamate transporters and enzymes, including GLT-1, GLAST, EAAC1, EAAT4, GluL, and GLS. Notably, GLT-1 expression increased ~ 5-fold in the control group and only ~ 2-fold in the paclitaxel group. These findings suggest that ceftriaxone enhances glutamate reuptake and reduces excitotoxicity in the cortex, contributing to pain relief. The study highlights a potential role for glutamate regulation in chronic pain mechanisms and supports further exploration of ceftriaxone as a candidate for managing glutamate-mediated neuropathic pain. This aligns with the broader goals of improving neurological health and promoting innovative therapeutic strategies.